Rubraca
Rubraca Gains Approval for Use in BRCA-Mutated mCRPC
The FDA granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) for patients with deleterious BRCA ...
MAY 20, 2020
FDA Grants New Indication for Rubraca
The FDA granted a new indication for Rubraca for the maintenance treatment of recurrent ovarian, fallopian tube or ...
APRIL 6, 2018
FDA Approves Rubraca for Advanced Ovarian Cancer
This is the first and only PARP inhibitor in the U.S. indicated to treat advanced ovarian cancer patients who have ...
DECEMBER 19, 2016
Load more